141 related articles for article (PubMed ID: 37278602)
1. Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre-dialysis chronic kidney disease or end-stage renal disease.
Bekku K; Nagasaki N; Tsuboi I; Takamoto A; Katayama S; Araki M
Int J Urol; 2023 Oct; 30(10):931-933. PubMed ID: 37278602
[No Abstract] [Full Text] [Related]
2. Editorial Comment on "Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre-dialysis chronic kidney disease or end-stage renal disease".
Kandori S
Int J Urol; 2023 Oct; 30(10):933. PubMed ID: 37431801
[No Abstract] [Full Text] [Related]
3. Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease.
Takagi T; Kondo T; Omae K; Iizuka J; Kobayashi H; Yoshida K; Hashimoto Y; Tanabe K
Int Urol Nephrol; 2016 Sep; 48(9):1421-7. PubMed ID: 27193433
[TBL] [Abstract][Full Text] [Related]
4. Renal cell carcinoma in chronic renal failure without dialysis treatment.
Sasagawa I; Nakada T; Terasawa Y; Takahashi H
Int Urol Nephrol; 1992; 24(6):607-11. PubMed ID: 1289269
[TBL] [Abstract][Full Text] [Related]
5. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.
Shaw LK; Wiele AJ; Sircar K; Wood CG; Msaouel P
Cancer Treat Res Commun; 2021; 27():100349. PubMed ID: 33725559
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor combination therapy leads to more nephrotoxicity in advanced renal cell carcinoma patients.
Song Y; Han S; Xu T
World J Urol; 2023 Jul; 41(7):1991-1992. PubMed ID: 37286737
[No Abstract] [Full Text] [Related]
7. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
8. Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma.
Ishihara H; Fukuda H; Tachibana H; Yoshida K; Kobayashi H; Takagi T; Iizuka J; Ishida H; Nagashima Y; Kondo T; Tanabe K
Clin Exp Nephrol; 2021 Jun; 25(6):674-682. PubMed ID: 33641007
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Nada A; Bhat R; Cousins J
Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review.
Osmán-García I; Congregado-Ruiz CB; Lendínez-Cano G; Baena-Villamarin C; Conde-Sanchez JM; Medina-López RA
Urol Int; 2020; 104(3-4):323-326. PubMed ID: 31914452
[TBL] [Abstract][Full Text] [Related]
11. Acquired cystic disease of the kidneys and renal cell carcinoma in chronic renal insufficiency without dialysis treatment.
Chung-Park M; Parveen T; Lam M
Nephron; 1989; 53(2):157-61. PubMed ID: 2812171
[TBL] [Abstract][Full Text] [Related]
12. Acquired cystic disease of kidney associated with renal cell carcinoma in chronic dialysis patients.
Lin JI; Saklayen M; Ehrenpresis M; Hillman NM
Urology; 1992 Feb; 39(2):190-3. PubMed ID: 1736519
[TBL] [Abstract][Full Text] [Related]
13. Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis.
Nouh MA; Kuroda N; Yamashita M; Hayashida Y; Yano T; Minakuchi J; Taniguchi S; Nomura I; Inui M; Sugimoto M; Kakehi Y
BJU Int; 2010 Mar; 105(5):620-7. PubMed ID: 19747356
[TBL] [Abstract][Full Text] [Related]
14. Renal tumors in end-stage renal disease: A comprehensive review.
Tsuzuki T; Iwata H; Murase Y; Takahara T; Ohashi A
Int J Urol; 2018 Sep; 25(9):780-786. PubMed ID: 30066367
[TBL] [Abstract][Full Text] [Related]
15. Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review.
Bando Y; Furukawa J; Hara T; Okamura Y; Terakawa T; Nakano Y; Fujisawa M
Urol Int; 2023; 107(3):321-326. PubMed ID: 36731453
[TBL] [Abstract][Full Text] [Related]
16. Clinical symptoms predict poor overall survival in chronic-dialysis patients with renal cell carcinoma associated with end-stage renal disease.
Ikezawa E; Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Takagi T; Omae K; Tanabe K
Jpn J Clin Oncol; 2014 Nov; 44(11):1096-100. PubMed ID: 25139162
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
[TBL] [Abstract][Full Text] [Related]
18. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
Sarkis J; Khalil N; Alkassis M
Future Oncol; 2021 Mar; 17(9):991-992. PubMed ID: 33533650
[No Abstract] [Full Text] [Related]
19. Renal cell carcinoma complicating long-term dialysis: computed tomography-guided aspiration cytology.
Nunez D; Yrizarry JM; Nadji M; Beerman R; Morillo G
J Comput Tomogr; 1986 Jan; 10(1):61-6. PubMed ID: 3943358
[TBL] [Abstract][Full Text] [Related]
20. Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single-center experience with four cases.
Omae K; Kondo T; Takagi T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
Hemodial Int; 2016 Jul; 20(3):E1-5. PubMed ID: 26833674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
